Ascent Scientific launches UCPH-101, a novel selective EAAT1 inhibitor

September 16, 2009 (PRLEAP.COM) Business News
Ascent Scientific ( announced the launch of UCPH-101, a new research tool that will aid research into glutamate neurotransmission. UCPH-101 is the latest addition to the Low-Cost Ligand range. It acts as a potent and selective blocker of the glutamate transporter EAAT1, and is greater than 400-fold selective over EAAT2 and EAAT3.

Steve Roome PhD, Commercial Director commented, "Ascent Scientific are proud to offer this exciting research tool to the scientific community. As well as making science affordable we are keen to introduce cutting-edge agonists and antagonists to the Low-Cost Ligand range. UCPH-101 joins a line up that includes VU0155041, a positive allosteric modulator at mGlu4, cis-PPDA, an NR2C/NR2D-preferring NMDA antagonist and UBP310, a GluK1 and GluK3 selective antagonist - all ground-breaking new tools that will advance glutamate research."

Iain Sandison, Science Director added, "UCPH-101 is available at very high purity (at least 99%). And of course, in keeping with our philosophy, we have introduced it at an affordable price!"

Contact: Steve Roome, Commercial Director +44 (0)117 982 99 88

About Ascent Scientific
Ascent Scientific offers a range of high quality receptor ligands and synthetic chemistry services at prices so low that as many researchers as possible will be able to afford them.

The Low-Cost Ligand range includes receptor ligands and signalling tools in research areas such as glutamate, GABA, ion channels, cannabinoids, opioids, 5-HT and more.

The Low-Cost Chemistry Service provides cost-effective custom synthesis of organic molecules, fluorescent labels, standards & references, stable isotope labels, receptor ligands and more.

Ascent Scientific operates out of UK headquarters close to Bristol, and a US Sales & Distribution office in New Jersey.

To request a new catalogue, visit our website, or contact customer service at